In this fast-paced podcast, two nationally-recognized clinical experts discuss the best way to manage patients who are newly diagnosed with multiple myeloma (NDMM), and the evolving role of currently approved and emerging agents for NDMM that target CD38. Through detailed evaluation of the most important clinical trials of CD38-targeting agents in NDMM, Dr. Joshua Richter and Dr. Andrew Yee address the possible impact of these new agents and their potential to change clinical practice in the upfront setting.

In this second installment, our two nationally-recognized clinical experts transition to critical factors that must be considered when treating multiple myeloma patients in the relapsed/refractory setting (RRMM). The central role of agents that target CD38 in RRMM, and the best use of both currently approved agents and combinations that include CD38-targeting agents in this patient population is discussed. In this fast-paced and dynamic podcast, Dr. Joshua Richter and Dr. Andrew Yee lead us through an engaging debate of how the numerous clinical trials investigating anti-CD38 antibodies in RRMM patients will impact clinical practice.

In the final installment of this podcast series, Dr. Richter and Dr. Yee engage in a wide-ranging discussion of the hottest topics in myeloma today, including how combination therapy will change as new agents are approved, and what types of combinations are most likely to result in the most improved outcomes with minimal risk of adverse events. Other timely topics that will be discussed include practical strategies for improving diversity in clinical trials and considerations of MRD as a tool for de-escalation of therapy in appropriate patients.